Clinical Diagnostics and Research Tools
-
23 Aug 2022 | North America | Frost Radar
Frost Radar™: US Liquid Biopsy, 2022
A Benchmarking System to Spark Companies to Action - Innovation that Fuels New Deal Flow and Growth Pipelines
The oncology space is maturing rapidly. With the arrival of blood-based assays for cancer screening and the emphasis on early detection, the liquid biopsy segment is seeing increased consolidation and high-impact acquisitions, such as Illumina and GRAIL, Exact Sciences and Thrive Earlier Detection, and Roche Foundation Medicine and Lexent Bio. Comp...
$4,950.00
